Pharmacoeconomic review report : Dupilumab (Dupixent) (Sanofi-Aventis Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Series:

Common drug review clinical review report.

Common drug review clinical review report

Language:

English

Subjects (All):

Drugs--Cost effectiveness.

Drugs.

Physical Description:

1 online resource.

Edition:

Final edition.

Place of Publication:

Ottawa, ON : CADTH, 2018.

Summary:

Dupilumab (Dupixent) is indicated for use in adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupilumab can be used with or without topical corticosteroids (TCS). The dosage form is 150 mg/mL solution in a pre-filled syringe, intended for patients to self-administer subcutaneously. The recommended dosage for adult patients is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg injected every other week. At the submitted price of 1,153.85 dollars per 300 mg dose, the first-year cost of dupilumab is 31,154 dollars, and 30,000 dollars annually thereafter. The manufacturer submitted a cost-utility analysis (CUA) of dupilumab as an add-on to current standard of care (SOC) in patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies.

Contents:

Abbreviations

Executive Summary

Background

Summary of Identified Limitations and Key Results

Conclusions

Information on the Pharmacoeconomic Submission

Summary of the Manufacturer's Pharmacoeconomic Submission

Manufacturer's Base Case

Summary of Manufacturer's Sensitivity Analyses

Limitations of Manufacturer's Submission

CADTH Common Drug Review Reanalyses

Issues for Consideration

Patient Input

Appendix 1. Cost Comparison

Appendix 2. Summary of Key Outcomes

Appendix 3. Additional Information

Appendix 4. Summary of Other Health Technology Assessment Reviews of Drug

Appendix 5. Reviewer Worksheets

References.

Notes:

Description based on publisher supplied metadata and other sources.